Sudoscan^® reclassifies cardiovascular risk in patients with type 2 diabetes mellitus according to the ESC 2023.

IF 1.6 Q4 ENDOCRINOLOGY & METABOLISM

Journal of Diabetes and Metabolic Disorders Pub Date : 2025-01-17 eCollection Date: 2025-06-01 DOI:10.1007/s40200-024-01548-7

Cesar Alejandro Figueroa-Perez, Maria Elena Romero-Ibarguengoitia, Arnulfo Garza-Silva, Iván Francisco Fernández-Chau, Andrea Belinda Cepeda-Medina, Sofía Garza-González, Dalia Gutierrez-González, Arnulfo González-Cantú

{"title":"Sudoscan® reclassifies cardiovascular risk in patients with type 2 diabetes mellitus according to the ESC 2023.","authors":"Cesar Alejandro Figueroa-Perez, Maria Elena Romero-Ibarguengoitia, Arnulfo Garza-Silva, Iván Francisco Fernández-Chau, Andrea Belinda Cepeda-Medina, Sofía Garza-González, Dalia Gutierrez-González, Arnulfo González-Cantú","doi":"10.1007/s40200-024-01548-7","DOIUrl":null,"url":null,"abstract":"Objectives: The objective of this study is to determine if the detection of DAN through Sudoscan® can reclassify cardiovascular risk in patients with T2DM according to the European Society of Cardiology guidelines 2023 (ESC 2023) compared to other risk scales.Methods: A retrospective cross-sectional analytical study was conducted on 161 patients with T2DM who had undergone Sudoscan® in a Northern Mexico Hospital between December 2022 and July 2023. We compared the cardiovascular risk with SCORE-2, SMART, ADVANCE, ASCVD plus, and Globo Risk scales.Results: Estimated cardiovascular risk according to the ESC 2023 without consideration of DAN was low for 91 (57%), moderate for 53 (33%), high for 11 (7%) and very high for 22 (3%) of patients. While inclusion of DAN resulted in low risk in 81 (51%), moderate in 46 (28%9, high in 9(5%) and very high risk for 25 ((16%), p = 0.004). The majority of patients were classified as low or moderate risk using other scales such as ASCVD plus, SCORE-2, Globo Risk, ADVANCE, and SMART.Conclusions: Sudoscan® enhances cardiovascular risk assessment in T2DM by accurately diagnosing microvascular complications, ensuring comprehensive patient evaluation.","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"50"},"PeriodicalIF":1.6000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748664/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes and Metabolic Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40200-024-01548-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The objective of this study is to determine if the detection of DAN through Sudoscan^® can reclassify cardiovascular risk in patients with T2DM according to the European Society of Cardiology guidelines 2023 (ESC 2023) compared to other risk scales.

Methods: A retrospective cross-sectional analytical study was conducted on 161 patients with T2DM who had undergone Sudoscan^® in a Northern Mexico Hospital between December 2022 and July 2023. We compared the cardiovascular risk with SCORE-2, SMART, ADVANCE, ASCVD plus, and Globo Risk scales.

Results: Estimated cardiovascular risk according to the ESC 2023 without consideration of DAN was low for 91 (57%), moderate for 53 (33%), high for 11 (7%) and very high for 22 (3%) of patients. While inclusion of DAN resulted in low risk in 81 (51%), moderate in 46 (28%9, high in 9(5%) and very high risk for 25 ((16%), p = 0.004). The majority of patients were classified as low or moderate risk using other scales such as ASCVD plus, SCORE-2, Globo Risk, ADVANCE, and SMART.

Conclusions: Sudoscan^® enhances cardiovascular risk assessment in T2DM by accurately diagnosing microvascular complications, ensuring comprehensive patient evaluation.

查看原文本刊更多论文

根据esc2023， Sudoscan®对2型糖尿病患者的心血管风险进行重新分类。

目的：本研究的目的是确定通过Sudoscan®检测DAN是否可以根据欧洲心脏病学会指南2023 （ESC 2023）与其他风险量表相比，对T2DM患者的心血管风险进行重新分类。方法：对2022年12月至2023年7月在墨西哥北部医院接受Sudoscan®治疗的161例T2DM患者进行回顾性横断面分析研究。我们将心血管风险与SCORE-2、SMART、ADVANCE、ASCVD plus和Globo风险量表进行比较。结果：在不考虑DAN的情况下，根据ESC 2023估计的心血管风险为91例（57%）为低，53例（33%）为中等，11例（7%）为高，22例（3%）为极高。而纳入DAN导致81例低危（51%）、46例中度（28%）、9例高危（5%）和25例非常高危（16%），p = 0.004。大多数患者使用ASCVD +、SCORE-2、Globo risk、ADVANCE和SMART等其他量表被分类为低或中度风险。结论：Sudoscan®通过准确诊断微血管并发症，提高T2DM心血管风险评估，确保对患者的全面评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Diabetes and Metabolic Disorders Medicine-Internal Medicine

CiteScore

4.80

自引率

3.60%

发文量

210

期刊介绍： Journal of Diabetes & Metabolic Disorders is a peer reviewed journal which publishes original clinical and translational articles and reviews in the field of endocrinology and provides a forum of debate of the highest quality on these issues. Topics of interest include, but are not limited to, diabetes, lipid disorders, metabolic disorders, osteoporosis, interdisciplinary practices in endocrinology, cardiovascular and metabolic risk, aging research, obesity, traditional medicine, pychosomatic research, behavioral medicine, ethics and evidence-based practices.As of Jan 2018 the journal is published by Springer as a hybrid journal with no article processing charges. All articles published before 2018 are available free of charge on springerlink.Unofficial 2017 2-year Impact Factor: 1.816.